Roche PT receives Investment Bank Analyst Rating Update
By Daniel ShvartsmanInvesting.com - Corporate earnings step to the center stage this week. Last week’s bank earnings saw mixed results, and the CPI report overshoot and subsequent...
by Daniel ShvartsmanInvesting.com - Wednesday trading saw the market continue its recovery from the volatile start to the trading year, with the S&P 500 finishing up nearly 1%...
When examining blue chip stocks, rarely do international companies get brought up. However, there are multiple overseas companies with an established track record of value...
Inflation worries continue to weigh on equity marketsEarnings season will likely increase volatilityETFs offer investors ability to diversifyEarnings season has started with...
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.